Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update

Jose Bagan; Crispian Scully; Vicente Sabater; Yolanda Jimenez

doi:10.1016/j.oraloncology.2009.01.002

Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update

Oral Oncol. 2009 Jul;45(7):551-4. doi: 10.1016/j.oraloncology.2009.01.002. Epub 2009 Feb 28.

Authors

Jose Bagan¹, Crispian Scully, Vicente Sabater, Yolanda Jimenez

Affiliation

¹ Valencia University, Valencia, Spain. bagan@uv.es

PMID: 19251474
DOI: 10.1016/j.oraloncology.2009.01.002

Abstract

Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is a severe complication seen most frequently in patients on intravenous bisphosphonates treatment for malignant diseases. High potency bisphosphonates are generally implicated and risk factors also include dental extractions. Prevention is of paramount importance. Management is controversial but there is little evidence basis and the consensus is to be conservative. Recent advances in this area are summarised in this concise review.

Publication types

Review

MeSH terms

Administration, Oral
Bone Density Conservation Agents / administration & dosage
Bone Density Conservation Agents / adverse effects*
Breast Neoplasms / drug therapy
Diphosphonates / administration & dosage
Diphosphonates / adverse effects*
Female
Humans
Injections, Intravenous
Jaw Diseases / chemically induced*
Jaw Diseases / epidemiology
Jaw Diseases / therapy
Male
Multiple Myeloma / drug therapy
Osteonecrosis / chemically induced*
Osteonecrosis / epidemiology
Osteonecrosis / therapy
Prostatic Neoplasms / drug therapy
Risk Factors

Substances

Bone Density Conservation Agents
Diphosphonates